Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease

Table 2

Comparison of hormonal data between patients with postglucose GH nadir over (group A) and below 0.4 mcg/L (group B) during longitudinal follow-up. Mean ± SD values are shown.

(a)

Parameters	Group A	Group B
	(GH-n ≥ 0.4)	(GH-n < 0.4)
	11	29	—
Sex (F/M)	8/3	17/12	ns
RT (y/n)	3/8	7/22	ns
Yrs. since disease remission	19.8 ± 9.7	15.1 ± 7.5	ns

(b)

	Preoperative	Phase 1	Phase 2	Phase 3	Preoperative	Phase 1	Phase 2	Phase 3
Basal GH; (μg/L)	25.9 ± 23.3	1.3 ± 0.9	1.3 ± 1.0	1.8 ± 1.6	18.2 ± 19.6	1.0 ± 0.9	0.9 ± 1.5	0.6 ± 0.7
Mean basal GH >2.5 μg/L; (y/n)	—	2/9	1/10	3/8	—	3/26	2/27	1/28
Postglucose nadir GH; (μg/L)	9.5 ± 6.5	0.76 ± 0.48	0.48 ± 0.28	0.51 ± 0.11	13.7 ± 13.5	0.30 ± 0.28	0.17 ± 0.15	0.11 ± 0.08
Time of postglucose GH nadir (min)	—	—	—	62.7 ± 36.6	—	—	—	63.8 ± 31.0
IGF-I; (SDS)	12.0 ± 6.8	0.4 ± 1.7	−0.7 ± 0.9	−0.4 ± 1.0	9.1 ± 4.7	0.6 ± 2.0	−2.8 ± 14.8	0.2 ± 1.7

F/M: female/male; RT: radiotherapy; y/n: yes/no; yrs.: years; GHD: GH deficiency.
Phase 1: at the time of remission.
Phase 2: at the time of the last available assessment with the GH assay standardized to IS 80/505.
Phase 3: after a long-term follow-up with ultrasensitive GH assay standardized to IS 98/574.
versus corresponding phase group B.
versus phase 1 same group.